T. Rowe Price Associates
EWTX icon

T. Rowe Price Associates’s Edgewise Therapeutics EWTX Stock Holding History

T. Rowe Price Associates’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.19M Buy
69,427
+12,112
+21% +$349K ﹤0.01% 1790
2025
Q4 		$1.42M Buy
57,315
+5,929
+12% +$119K ﹤0.01% 1918
2025
Q3 		$834K Buy
51,386
+704
+1% +$9.98K ﹤0.01% 2141
2025
Q2 		$665K Sell
50,682
-244,199
-83% -$3.52M ﹤0.01% 2167
2025
Q1 		$6.49M Buy
294,881
+265,831
+915% +$6.97M ﹤0.01% 1201
2024
Q4 		$776K Buy
29,050
+5,242
+22% +$167K ﹤0.01% 2081
2024
Q3 		$636K Buy
23,808
+722
+3% +$14.4K ﹤0.01% 2163
2024
Q2 		$416K Buy
23,086
+6,662
+41% +$116K ﹤0.01% 2265
2024
Q1 		$300K Sell
16,424
-109,647
-87% -$1.74M ﹤0.01% 2434
2023
Q4 		$1.38M Buy
126,071
+367
+0.3% +$2.58K ﹤0.01% 1713
2023
Q3 		$722K Buy
125,704
+1,024
+0.8% +$6.96K ﹤0.01% 1947
2023
Q2 		$968K Buy
124,680
+2,110
+2% +$17.8K ﹤0.01% 1827
2023
Q1 		$819K Sell
122,570
-135,756
-53% -$1.26M ﹤0.01% 1883
2022
Q4 		$2.31M Buy
258,326
+2,088
+0.8% +$19.6K ﹤0.01% 1418
2022
Q3 		$2.52M Sell
256,238
-92,985
-27% -$940K ﹤0.01% 1371
2022
Q2 		$2.78M Sell
349,223
-552
-0.2% -$4.17K ﹤0.01% 1527
2022
Q1 		$3.39M Buy
+349,775
New +$4.5M ﹤0.01% 1545

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates's EWTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Edgewise Therapeutics (EWTX) stake by 21% in Q1 2026, buying an estimated $349K and bringing the position to 69,427 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

T. Rowe Price Associates first reported a position in EWTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $6.49M in Q1 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • T. Rowe Price Associates held 69,427 shares of Edgewise Therapeutics worth $2.19M as of Q1 2026.
  • T. Rowe Price Associates bought 12,112 Edgewise Therapeutics shares in Q1 2026, an estimated $349K.
  • Edgewise Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1790 holding.
  • T. Rowe Price Associates first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • T. Rowe Price Associates's Edgewise Therapeutics position peaked at $6.49M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.